Koshinski Asset Management
IBRX icon

Koshinski Asset Management’s ImmunityBio IBRX Stock Holding History

Koshinski Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41
Closed -$230 – 1222
2022
Q1 		$230 Hold
41
– – ﹤0.01% 2134
2021
Q4 		$249 Hold
41
– – ﹤0.01% 2140
2021
Q3 		$399 Buy
+41
New +$451 ﹤0.01% 2140

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Koshinski Asset Management's IBRX Position: Q2 2022 in Review

Koshinski Asset Management sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 41 shares — an estimated $230 sold.

Koshinski Asset Management first reported a position in IBRX in Q3 2021 and held it in 3 quarters. The position peaked at $399 in Q3 2021. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

  • Koshinski Asset Management reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 41 ImmunityBio shares in Q2 2022, an estimated $230.
  • Koshinski Asset Management first reported a position in ImmunityBio in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's ImmunityBio position peaked at $399 in Q3 2021.
  • 131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.